bioRxivCancer Biology
Early-stage lung adenocarcinoma is driven by an injury-associated, plastic cell state dependent on a KRAS-ITGA3-SRC axis
A. L. Moye, A. F. M. Dost, R. Ietswaart, S. Sengupta, V. Ya, C. Aluya, C. G. Fahey, S. M. Louie, M. Paschini, C. F. Kim
Abstract
Glycine 12 mutations in the GTPase KRAS (KRASG12) are a known initiating event for lung adenocarcinoma (LUAD) with broad clinical relevance. KRASG12 mutations promote cell-intrinsic rewiring of the lung alveolar type II progenitor (AT2) cells, but to what extent such changes interplay with pathways essential for lung homeostasis and cell fate is unclear. We used single-cell RNA-seq (scRNA-seq) from AT2-mesenchyme organoid co-cultures, mouse models, and stage IA LUAD patient samples to identify conserved regulators of AT2 cell transcriptional dynamics and the impact of KRASG12D with temporal resolution. In AT2WT organoids, a transient injury/plasticity state preceded AT2 self-renewal and AT1 differentiation. Early-stage AT2KRAS cells exhibited perturbed gene expression dynamics most noted by retention of the injury/plasticity state. At later time points in tumorigenesis, AT2KRAS cells consisted of heterogeneous populations that could be defined by either the injury state or high expression of an AT2 cell signature. The injury state in AT2KRAS cells of LUAD in patients, mice, and organoids was distinguishable from AT2WT states by altered receptor expression, including co-expression of ITGA3 and SRC. The combination of clinically relevant KRASG12D and SRC inhibitors to target the oncogenic injury cell state impaired AT2KRAS organoid growth. Thus, an injury/plasticity signature characterized as an essential step in lung repair is used during alveolar cell self-renewal and during initiation and progression of LUAD. Early-stage lung cancer may be susceptible to intervention by targeting the oncogenic-specific nature of this cell state.
- organism: mouse
- organism: human
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An atlas of epithelial cell states and plasticity in lung adenocarcinoma
- Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma
Z. Li, X. Zhuang, … T. Tammela·bioRxiv·Sep 29, 2023
- Alveolar epithelial type 1 cells serve as a cell of origin for lung adenocarcinoma with distinct molecular and phenotypic presentation
M. Yang, H. Shen, … C. N. Marconett·bioRxiv·Oct 29, 2022
- Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
X. Tong, A. S. Patel, … H. Ji·bioRxiv·Sep 7, 2023
- Aging directs the differential evolution of KRAS-driven lung adenocarcinoma
Felicia Lazure, Stanislav Drápela, … Ana P. Gomes·bioRxiv·Jan 20, 2025
- Diverse routes of Club cell evolution in lung adenocarcinoma
Y. Chen, R. Toth, … R. Sotillo·bioRxiv·Jun 10, 2021